Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction? - PubMed (original) (raw)
Review
doi: 10.1038/nrc1799.
Affiliations
- PMID: 16491070
- DOI: 10.1038/nrc1799
Review
Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction?
Stephen B Baylin et al. Nat Rev Cancer. 2006 Feb.
Abstract
Chromatin alterations have been associated with all stages of tumour formation and progression. The best characterized are epigenetically mediated transcriptional-silencing events that are associated with increases in DNA methylation - particularly at promoter regions of genes that regulate important cell functions. Recent evidence indicates that epigenetic changes might 'addict' cancer cells to altered signal-transduction pathways during the early stages of tumour development. Dependence on these pathways for cell proliferation or survival allows them to acquire genetic mutations in the same pathways, providing the cell with selective advantages that promote tumour progression. Strategies to reverse epigenetic gene silencing might therefore be useful in cancer prevention and therapy.
Similar articles
- Epigenetic silencing mediated by CpG island methylation: potential as a therapeutic target and as a biomarker.
Teodoridis JM, Strathdee G, Brown R. Teodoridis JM, et al. Drug Resist Updat. 2004 Aug-Oct;7(4-5):267-78. doi: 10.1016/j.drup.2004.06.005. Drug Resist Updat. 2004. PMID: 15533764 Review. - Epigenetic changes in cancer and preneoplasia.
Herman JG. Herman JG. Cold Spring Harb Symp Quant Biol. 2005;70:329-33. doi: 10.1101/sqb.2005.70.036. Cold Spring Harb Symp Quant Biol. 2005. PMID: 16869769 Review. - Aberrant gene silencing in tumor progression: implications for control of cancer.
Baylin SB, Chen WY. Baylin SB, et al. Cold Spring Harb Symp Quant Biol. 2005;70:427-33. doi: 10.1101/sqb.2005.70.010. Cold Spring Harb Symp Quant Biol. 2005. PMID: 16869780 Review. - Epigenetic drivers and genetic passengers on the road to cancer.
Sawan C, Vaissière T, Murr R, Herceg Z. Sawan C, et al. Mutat Res. 2008 Jul 3;642(1-2):1-13. doi: 10.1016/j.mrfmmm.2008.03.002. Epub 2008 Mar 25. Mutat Res. 2008. PMID: 18471836 Review. - Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.
Sigalotti L, Fratta E, Coral S, Cortini E, Covre A, Nicolay HJ, Anzalone L, Pezzani L, Di Giacomo AM, Fonsatti E, Colizzi F, Altomonte M, Calabrò L, Maio M. Sigalotti L, et al. J Cell Physiol. 2007 Aug;212(2):330-44. doi: 10.1002/jcp.21066. J Cell Physiol. 2007. PMID: 17458893 Review.
Cited by
- Signaling pathways involved in colorectal cancer: pathogenesis and targeted therapy.
Li Q, Geng S, Luo H, Wang W, Mo YQ, Luo Q, Wang L, Song GB, Sheng JP, Xu B. Li Q, et al. Signal Transduct Target Ther. 2024 Oct 7;9(1):266. doi: 10.1038/s41392-024-01953-7. Signal Transduct Target Ther. 2024. PMID: 39370455 Free PMC article. Review. - Gastrointestinal Malignancy: Genetic Implications to Clinical Applications.
Trembath HE, Yeh JJ, Lopez NE. Trembath HE, et al. Cancer Treat Res. 2024;192:305-418. doi: 10.1007/978-3-031-61238-1_15. Cancer Treat Res. 2024. PMID: 39212927 Review. - Epigenome-wide association study of prostate cancer in African American men identified differentially methylated genes.
Berglund A, Yamoah K, Eschrich SA, Falahat R, Mulé JJ, Kim S, Matta J, Dutil J, Ruiz-Deya G, Ortiz Sanchez C, Wang L, Park H, Banerjee HN, Lotan T, Barry KH, Putney RM, Kim SJ, Gwede C, Kresovich JK, Kim Y, Lin HY, Dhillon J, Chakrabarti R, Park JY. Berglund A, et al. Cancer Med. 2024 Aug;13(16):e70044. doi: 10.1002/cam4.70044. Cancer Med. 2024. PMID: 39162297 Free PMC article. - Unveiling critical structural features for effective HDAC8 inhibition: a comprehensive study using quantitative read-across structure-activity relationship (q-RASAR) and pharmacophore modeling.
Khatun S, Dasgupta I, Islam R, Amin SA, Jha T, Dhaked DK, Gayen S. Khatun S, et al. Mol Divers. 2024 Aug;28(4):2197-2215. doi: 10.1007/s11030-024-10903-y. Epub 2024 Jun 13. Mol Divers. 2024. PMID: 38871969 - An improved epigenetic counter to track mitotic age in normal and precancerous tissues.
Zhu T, Tong H, Du Z, Beck S, Teschendorff AE. Zhu T, et al. Nat Commun. 2024 May 17;15(1):4211. doi: 10.1038/s41467-024-48649-8. Nat Commun. 2024. PMID: 38760334 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources